Advanced in Myelodysplastic Syndrome (MDS)

Ping Wu

Guangdong Provincial Key Laboratory Of Translational Medicine In Lung Cancer, 
Guangzhou, CN 
Advanced in Myelodysplastic Syndrome (MDS)
Guangdong Provincial Key Laboratory Of Translational Medicine In Lung Cancer, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Ping Wu practices in Guangzhou, China. Wu is rated as an Advanced expert by MediFind in the treatment of Myelodysplastic Syndrome (MDS). Their top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Chronic Myelogenous Leukemia (CML).

Their clinical research consists of co-authoring 34 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles in the study of Myelodysplastic Syndrome (MDS).

Locations

Guangdong Provincial Key Laboratory Of Translational Medicine In Lung Cancer, Guangzhou, 510080, China
Other Locations
Hengyang, China
Nanqiao, 201404, China
Key Laboratory Of Prevention And Management Of Chronic Kidney Disease Of Zhanjiang City, Zhanjiang, China
Wuxi, 214000, China
Cangzhou, China
Shanghai, 200065, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

34 Total Publications

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial.
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial.
Journal: Trials
Published: May 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile